1.22

6.15% -0.08

Pre-market: 1.25 0.03 +2.46%

Inovio Pharmaceuticals Inc (INO)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Inovio Pharmaceuticals Inc stock is traded at $1.22, with a volume of 5.32M. It is down -6.15% in the last 24 hours and up +2.52% over the past month. Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.

Previous Close:

$1.30

Open:

$1.34

24h Volume:

5.32M

Relative Volume:

2.33

Market Cap:

$100.37M

Revenue:

$65,300

Net Income/Loss:

$-84.95M

P/E Ratio:

-0.6311

EPS:

-1.9332

Net Cash Flow:

$-88.92M

1W Performance:

-14.69%

1M Performance:

+2.52%

6M Performance:

-35.45%

1Y Performance:

-40.49%

1-Day Range:

$1.21

$1.445

1-Week Range:

$1.21

$1.47

52-Week Range:

$1.03

$2.9789

Inovio Pharmaceuticals Inc Stock (INO) Company Profile

Name

Inovio Pharmaceuticals Inc

Sector

Healthcare (1109)

Industry

Biotechnology (612)

Phone

(858) 410-3134

Address

660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA

Employee

112

Twitter

@inoviopharma

Next Earnings Date

2026-05-13

Latest SEC Filings

INO's Discussions on Twitter

Compare INO vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
INO Inovio Pharmaceuticals Inc	1.22	106.96M	65,300	-84.95M	-88.92M	-1.9332
VRTX Vertex Pharmaceuticals Inc	436.58	110.90B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	629.68	73.20B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	776.26	49.71B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	286.27	38.32B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	144.37	30.97B	742.00K	-1.37B	-1.07B	-7.0731

Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-09-25	Initiated	Piper Sandler	Overweight
May-14-24	Initiated	Stephens	Overweight
Jan-25-24	Upgrade	Oppenheimer	Perform → Outperform
Nov-09-22	Downgrade	Maxim Group	Buy → Hold
Nov-01-22	Downgrade	BofA Securities	Neutral → Underperform
Jul-19-22	Resumed	RBC Capital Mkts	Sector Perform
May-11-22	Downgrade	Oppenheimer	Outperform → Perform
Jan-21-22	Upgrade	BofA Securities	Underperform → Neutral
Dec-29-21	Resumed	Jefferies	Hold
Sep-10-21	Downgrade	BofA Securities	Neutral → Underperform
Jun-24-21	Initiated	Jefferies	Hold
Mar-23-21	Initiated	BofA Securities	Neutral
Feb-12-21	Initiated	Oppenheimer	Outperform
Nov-17-20	Downgrade	ROTH Capital	Neutral → Sell
Nov-10-20	Upgrade	ROTH Capital	Sell → Neutral
Sep-28-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-28-20	Upgrade	Maxim Group	Hold → Buy
Jul-01-20	Downgrade	Maxim Group	Buy → Hold
Jul-01-20	Downgrade	ROTH Capital	Neutral → Sell
Jun-29-20	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-26-20	Downgrade	Stifel	Buy → Hold
May-21-20	Initiated	The Benchmark Company	Buy
Apr-30-20	Downgrade	ROTH Capital	Buy → Neutral
Mar-13-20	Downgrade	Piper Sandler	Overweight → Neutral
Mar-13-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Dec-19-19	Initiated	ROTH Capital	Buy
Feb-15-18	Reiterated	Maxim Group	Buy
Oct-18-17	Initiated	RBC Capital Mkts	Outperform
Sep-06-17	Initiated	Citigroup	Buy
Jun-08-17	Upgrade	Piper Jaffray	Neutral → Overweight
May-24-17	Reiterated	Maxim Group	Buy
Mar-16-17	Upgrade	Maxim Group	Hold → Buy
Mar-16-17	Downgrade	Piper Jaffray	Overweight → Neutral

View All

Inovio Pharmaceuticals Inc Stock (INO) Latest News

May 18, 2026

Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch

May 18, 2026

Inovio (NASDAQ: INO) CEO nets shares from RSU vesting and tax withholding - Stock Titan

May 18, 2026

Inovio Pharmaceuticals (INO) CFO exercises 4,771 RSUs and has 2,571 shares withheld for taxes - Stock Titan

May 18, 2026

INOVIO (NASDAQ: INO) CSO settles RSUs, shares withheld for tax - Stock Titan

May 18, 2026

INOVIO (NASDAQ: INO) CMO vests RSUs and withholds shares for taxes - Stock Titan

May 18, 2026

May 16, 2026

Inovio Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:INO) 2026-05-16 - Seeking Alpha

May 16, 2026

INO Should I Buy - Intellectia AI

May 16, 2026

May 15, 2026

Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch

May 15, 2026

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q1 2026 Earnings Call Transcript - Insider Monkey

May 15, 2026

Highbridge reports 6.19M warrant‑issued shares in Inovio (INO) - Stock Titan

May 15, 2026

May 14, 2026

Investigation Alert: Investors who hold shares of Inovio - openPR.com

May 14, 2026

Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

May 14, 2026

INOVIO Shares Drop 10% After Discounted $25 Million Public Offering - MSN

May 14, 2026

Inovio Pharmaceuticals stock (US45773H2013): Q1 2026 results and INO-3107 FDA review - AD HOC NEWS

May 14, 2026

Inovio: All Eyes On INO-3107 As Binary FDA Decision Looms (NASDAQ:INO) - Seeking Alpha

May 14, 2026